drugset / Trial / NCT00047216
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
Open-labelTreatment
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer.
Timeline
- Start
- 2002-11
- Primary completion
- 2006-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tipifarnib | Small molecule | — | Oral |